Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG vs ATLG for GVHD Prophylaxis in Elderly AML/MDS Patients
NCT06083129Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2023
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of antithymocyte globulin rabbit, antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2023; status: recruiting.
02
Drugs
antithymocyte globulin rabbitantithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06083129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083129.